Semaglutide Dosing Guide: Titration, Vial Math & What the Trials Show
Semaglutide is the drug that started the GLP-1-class era, and unlike most of this library it has the full evidence stack: large randomised trials, an FDA label, and cardiovascular outcome data. This guide covers the titration schedule that actually works, the vial math for compounded and grey-market formats, what the trials really showed, and the interactions worth knowing about.
Also known as Ozempic, Wegovy, Rybelsus
Semaglutide quick start
- Route
- Subcutaneous injection, once weekly, any time of day, with or without food. Commercial pens (Ozempic, Wegovy) are ready to use; an oral tablet exists (Rybelsus) with much lower bioavailability. Vials — compounded or grey-market — are reconstituted and drawn with an insulin syringe.
- Dose context
- 0.25 mg weekly to start, titrating stepwise to a maintenance dose of 1.0–2.4 mg weekly. The label schedule holds each step 4 weeks; the community holds steps longer whenever nausea says so, and that patience is what separates people who stay on it from people who quit in month one.
- Measure
- A 5 mg vial in 2.0 mL of bacteriostatic water gives 2.5 mg/mL — a 0.25 mg starting dose is 10 units on a U-100 syringe.
- Cycle context
- Not a cycled compound. The trials ran continuously for 68–104 weeks, and stopping typically reverses much of the weight loss within a year — this is a long-term commitment, not a cut.
- Status
- FDA-approved: type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), with a cardiovascular risk-reduction indication added after the SELECT trial. Prescription only.
Dosing context and schedule
What follows is drawn from the published record and from what the community has settled on. Reference points, not prescriptions — your situation is yours.
| Phase | Dose | Volume | Units (U-100) | Note |
|---|---|---|---|---|
| Weeks 1–4 | 0.25 mg/week | 0.10 mL | 10 units | 5 mg vial in 2.0 mL. This dose is for gut adaptation, not effect — do not judge the drug here. |
| Weeks 5–8 | 0.5 mg/week | 0.20 mL | 20 units | The first dose many people feel. Some stay here for months and lose plenty. |
| Weeks 9–12 | 1.0 mg/week | 0.40 mL | 40 units | A common long-term maintenance dose. |
| Weeks 13–16 | 1.7 mg/week | 0.68 mL | 68 units | Only step up if loss has stalled AND the current dose is comfortable. |
| Week 17+ | 2.4 mg/week | 0.96 mL | 96 units | The full Wegovy maintenance dose from the STEP trials. Many people never need it. |
Cycle structures
| Approach | Duration | Review point | Note |
|---|---|---|---|
| Label titration | 16 weeks to full dose | Every 4 weeks | The schedule from the Wegovy label. Each step held a minimum of 4 weeks. |
| Slow titration | 6–12 months to maintenance | Each step change | The community default, especially for women — hold every step until side effects are quiet, then decide whether you even need the next one. |
| Lowest effective dose | Ongoing | Monthly weight + symptoms | Stay at whatever dose is producing steady loss. The label maximum is a ceiling, not a target. |
For women
What people actually run
The converged protocol
Start at 0.25 mg weekly and stay there a full month no matter how good you feel. Titrate one step at a time, holding each until side effects are boring. Most people settle between 1.0 and 2.4 mg. Protein first at every meal, resistance training non-negotiable, and slow the titration rather than pushing through nausea.
The single most repeated piece of community wisdom: almost every bad semaglutide experience is a titration problem. Nausea, vomiting and the misery stories come overwhelmingly from moving up too fast. The people who do well treat the schedule as a speed limit, not a race.
Muscle loss is the quiet failure mode. In the trials a meaningful share of total weight lost was lean mass, and the community answer has converged hard: about 1.6 g protein per kg of goal weight per day and lifting at least twice a week. People who skip this end up lighter and weaker, then blame the drug.
The plateau is normal and expected — loss flattens as your body settles at a new set point. The community response is to first check the basics (protein, sleep, actual calorie intake) before reaching for a dose increase, because the next step up costs side-effect budget you may want later.
On compounded and grey-market vials: since the FDA declared the semaglutide shortage resolved in early 2025, mass pharmacy compounding has wound down, and much of what circulates now is research-chemical material of unverified identity and concentration. If you hold a vial, verify the concentration before drawing anything — the same syringe markings mean different milligrams at different concentrations, and that is exactly the arithmetic DoseIQ does for you.
What the evidence actually says
The honest picture
Semaglutide is the rare compound in this library where the evidence question is settled at scale. STEP 1 randomised roughly 1,960 adults and found about 15% average body-weight reduction at 2.4 mg over 68 weeks against 2.4% on placebo. SUSTAIN-6 and then SELECT — the latter in over 17,000 adults with cardiovascular disease and no diabetes — showed about a 20% reduction in major cardiovascular events. That is a real outcomes benefit, not a surrogate marker.
What the trials also show, and marketing does not repeat: average is not typical. Responses spread widely — some people lose 25%, a meaningful minority lose little. Weight regain after stopping is the norm, with the STEP 1 extension showing most of the loss reversing within a year off drug. And a substantial fraction of the weight lost is lean mass unless you actively defend it with protein and training.
The genuinely open questions are about the format many people actually use, not the molecule: grey-market vials have no identity or sterility assurance, and no trial has studied the stop-start pattern that budget realities force on some users.
How it is proposed to work
Semaglutide is a GLP-1 receptor agonist — a modified analogue of a gut hormone released after eating. It slows gastric emptying, increases insulin secretion when glucose is elevated, suppresses glucagon, and acts on appetite circuits in the hypothalamus and brainstem. The subjective effect people describe is not willpower but silence: the food noise stops.
The molecule is engineered for a roughly 7-day half-life — a fatty-acid chain binds it to albumin, protecting it from degradation — which is what allows weekly dosing and also why steady state takes 4–5 weeks to reach after any dose change. This is the pharmacological reason the 4-week hold per step is not bureaucracy.
The cardiovascular benefit in SELECT appears only partly explained by weight loss itself; anti-inflammatory and direct vascular effects are under active study. That mechanism question is unresolved; the outcome finding is not.
When to talk to a doctor first
Most people run Semaglutide without incident. These are the specific situations where it is worth a conversation with a clinician before you start — not reasons to rule it out, but reasons to go in with your eyes open.
- A personal or family history of medullary thyroid carcinoma or MEN2 — this is the boxed warning, based on rodent C-cell tumours. The human relevance is debated, but the label is unambiguous: do not use.
- A history of pancreatitis — GLP-1-class drugs carry a pancreatitis signal. Sudden, severe abdominal pain radiating to the back means stop and get seen the same day.
- Pregnancy, or planning it — the label says stop at least 2 months before trying to conceive. Rapid weight loss itself is also contraindicated in pregnancy.
- Active gallbladder disease — rapid weight loss raises gallstone risk, and the trials showed more gallbladder events on drug than placebo.
- Diabetic retinopathy — rapid glucose improvement can transiently worsen it; this needs ophthalmology in the loop, not avoidance of treatment.
- If you take insulin or a sulfonylurea — the combination raises hypoglycemia risk and usually means the other drug's dose comes down. That is a prescriber conversation before the first injection, not after the first low.
What to expect
Most of what people notice is mild and settles within the first week or two. The list below is ordered by how often it actually comes up, so you know what is routine and what is worth paying attention to.
Common, and usually settles
- Nausea — the signature effect, worst in the days after a dose increase, easing as you adapt. Dose-related and titration-managed.
- Constipation — often the longer-lasting complaint. Fibre, water and magnesium are the community standbys.
- Fatigue in the first weeks, usually resolving.
- Burping, reflux and early fullness — gastric emptying is slowed; smaller meals fix most of it.
Less common
- Vomiting and diarrhea — usually a sign the titration went up too fast.
- Hair shedding around months 3–5 — a response to rapid weight loss itself (telogen effluvium), not a direct drug effect; it regrows.
- Injection site reactions.
- Dizziness, often from eating and drinking too little — the appetite suppression can overshoot.
Rare — stop and get advice
- Pancreatitis — severe, persistent abdominal pain, often radiating to the back, sometimes with vomiting. Emergency assessment, not wait-and-see.
- Gallbladder disease — right-upper-quadrant pain after fatty meals warrants an ultrasound.
- Severe hypoglycemia when combined with insulin or sulfonylureas.
- Dehydration and kidney injury from persistent vomiting — the label carries a renal warning for exactly this chain of events.
Known interactions
Interactions involving Semaglutide's drug class that DoseIQ screens for. Each one cites where it comes from — an FDA label section or the published record — because an interaction warning you can't trace is just noise.
Semaglutide, tirzepatide and retatrutide all cut appetite and glucose while the insulin dose was sized for the old intake — the mismatch is how hypos happen.
What to do: Prescribers usually reduce insulin when a GLP-1-class drug starts. Monitor glucose closely and have that conversation.
Source: FDA labels, semaglutide/tirzepatide §7
Sulfonylureas force insulin release regardless of glucose; adding any GLP-1-class drug on top is the classic hypoglycemia setup.
What to do: The sulfonylurea dose is usually reduced or stopped when a GLP-1-class drug starts — ask your prescriber if that conversation hasn't happened.
Source: FDA labels, semaglutide/tirzepatide §7
Growth hormone raises glucose and insulin resistance — it works directly against glucose-lowering medication.
What to do: Fasting glucose and HbA1c are worth tracking; medication doses sometimes need adjusting. Your prescriber should know GH peptides are in the picture.
Source: GH pharmacology; tesamorelin label §7
Even short prednisone courses raise glucose; diabetes control commonly loosens during a course.
What to do: Monitor glucose during the course; prescribers often adjust doses temporarily.
Source: FDA label, prednisone §7
The whole GLP-1 class — semaglutide, tirzepatide, retatrutide — delays gastric emptying, which changes how narrow-margin oral drugs (thyroid, warfarin, the pill) absorb.
What to do: Keep timing consistent, and re-check the relevant lab (TSH, INR) a few weeks after starting or increasing the dose.
Source: FDA labels, GLP-1 class §7
Levothyroxine dosing tracks body weight — significant weight loss on any GLP-1-class drug commonly means the old dose becomes too high.
What to do: Re-check TSH after meaningful weight change rather than waiting for symptoms.
Source: Levothyroxine dosing guidance (weight-based)
Both suppress appetite; together intake can drop genuinely too low without feeling like anything is wrong.
What to do: Track weight and actually eat protein on schedule — hunger stops being a reliable signal on this combination.
Source: Class pharmacology; widely reported in practice
The racing heart that warns of a low is exactly what a beta-blocker suppresses — lows sneak up quietly.
What to do: Anyone on this combination should know sweating remains a reliable warning sign when the heart rate isn't.
Source: FDA label, metoprolol §7
Lithium levels track hydration, and a rough titration week — nausea, vomiting, big drops in intake — concentrates lithium.
What to do: Drink deliberately during dose increases, and treat persistent vomiting as a reason to check a lithium level, not just wait out.
Source: Lithium label (volume depletion); GLP-1 class GI profile
Olanzapine and quetiapine drive weight and glucose up; GLP-1-class drugs are increasingly co-prescribed to counter exactly that.
What to do: Usually intentional — the job here is tracking: fasting glucose, HbA1c and lipids tell you whether the plan is working.
Source: Class pharmacology; current prescribing practice
Reconstitution guide
Semaglutide ships as a lyophilised powder and gets mixed with bacteriostatic water before use. How much water you add sets the concentration, which sets how many syringe units make up each dose. One unit on a U-100 syringe is 0.01 mL — the tables below do the arithmetic for the vial sizes you are most likely to be holding.
10mg vial most common
| Water added | Concentration | 0.25mg |
|---|---|---|
| 1mL (common) | 10 mg/mL | 0.03 mL 2.5 units |
| 2mL | 5 mg/mL | 0.05 mL 5 units |
5mg vial
| Water added | Concentration | 0.25mg |
|---|---|---|
| 1mL (common) | 5 mg/mL | 0.05 mL 5 units |
| 2mL | 2.5 mg/mL | 0.10 mL 10 units |
Standard steps
- Inspect the vialConfirm the label and that the powder cake is intact. Do not use a cracked or compromised vial.
- Let it reach room temperatureSitting out for a few minutes reduces condensation inside the vial when the seal is broken.
- Disinfect both stoppersWipe the compound vial and the bacteriostatic water vial with a fresh alcohol swab and let them air-dry.
- Draw the bacteriostatic waterUse a sterile syringe to draw the volume you have chosen from the reconstitution table.
- Add the water down the vial wallInject slowly so it runs down the inside wall rather than spraying directly onto the powder. This limits foaming.
- Dissolve gentlySwirl or roll the vial between your hands until the cake dissolves. Never shake — agitation damages peptide bonds. The solution should end up clear.
- Label and refrigerateWrite the reconstitution date and concentration on the vial. Store at 2–8°C. Do not freeze.
Timeline and monitoring
- Weeks 1–4Appetite quiets — many people notice the "food noise" drop within days. Weight change is modest at the starting dose; that is by design.
- Weeks 5–16Steady loss through titration, typically 0.5–1% of body weight per week. Side effects spike briefly at each step and settle.
- Months 4–12The bulk of the loss. STEP 1 curves keep falling to about week 60 before flattening.
- Beyond a yearMaintenance. The trials support continued use for weight kept off; stopping typically reverses most of the loss within a year.
Bloodwork worth discussing
Markers a clinician may consider relevant before or during a protocol. This is context for a conversation, not a self-ordering list.
| Marker | Why it is relevant |
|---|---|
| HbA1c and fasting glucose | Baseline glycemic status, and tracks the metabolic improvement that is half the point. |
| Lipid panel | Usually improves with weight loss; worth documenting. |
| Comprehensive metabolic panel | Kidney function baseline — relevant given the dehydration-renal warning. |
| Lipase/amylase if symptomatic | Not routinely screened, but the first test that matters if abdominal pain raises the pancreatitis question. |
| TSH if on levothyroxine | Slowed gastric emptying can change levothyroxine absorption; thyroid patients should recheck after starting. |
Supplies by cycle length
A 5 mg vial provides 20 weeks at 0.25 mg, 10 weeks at 0.5 mg, 5 weeks at 1.0 mg, or about 2 weeks at 2.4 mg.
| Cycle length | Vials | Syringes | BAC water | Planning note |
|---|---|---|---|---|
| First 8 weeks | 1 × 5 mg | 8 syringes | 1 × 10 mL bottle | Covers the 0.25 and 0.5 mg steps with room to spare. |
| 12 weeks at 1.0 mg | 3 × 5 mg | 12 syringes | 1 × 10 mL bottle | One vial per ~5 weeks at this dose. |
| 12 weeks at 2.4 mg | 6 × 5 mg or 3 × 10 mg | 12 syringes | 1 × 10 mL bottle | The top dose burns through supply quickly — plan refills ahead of the step-up. |
What the research record contains
STEP 1 (NEJM, 2021): 2.4 mg weekly in ~1,960 adults with obesity — 14.9% mean weight reduction at 68 weeks versus 2.4% placebo.
SUSTAIN programme: established the type 2 diabetes indication with consistent HbA1c and weight benefits across comparators.
SELECT (NEJM, 2023): 17,604 adults with cardiovascular disease and overweight/obesity but no diabetes — 20% relative reduction in major adverse cardiovascular events. The first weight-loss drug to show a hard cardiovascular outcomes benefit.
STEP 1 extension: after withdrawal, participants regained roughly two-thirds of lost weight within a year — the strongest evidence that this is maintenance pharmacology, not a course of treatment.
Label warnings are trial-derived: boxed warning for thyroid C-cell tumours (rodent finding, human relevance unestablished), pancreatitis, gallbladder disease, hypoglycemia in combination, and acute kidney injury secondary to volume loss.
Storage and handling
- Commercial pens: refrigerate at 2–8°C; in-use pens may be kept at room temperature within the label window for the specific product.
- Lyophilised vials: refrigerate; stable cold, dry and dark.
- Reconstituted vials: refrigerate, use within 28–30 days (bacteriostatic water), never freeze.
- Label every vial with date and concentration — with several vial strengths circulating, an unlabelled vial is a dosing error waiting to happen.
Troubleshooting
The nausea is rough. Push through?
No — drop back to the previous dose and hold there for another 2–4 weeks. The dose-response for weight loss is far shallower than people assume; the dose-response for misery is steep. Also try injecting the night before your lightest eating day.
I missed a weekly dose.
The label rule: if it is within 5 days, take it and keep your schedule. Past 5 days, skip it and take the next on schedule. With a 7-day half-life the level fades gradually — no doubling up.
I stopped losing weight at 1.0 mg.
First audit protein, sleep and actual intake for two honest weeks. If those check out, the next titration step is the tool. A plateau is the body settling, not the drug failing.
My vial says 5 mg but the pharmacy one said 2.5 mg/mL. Which numbers do I use?
Total milligrams in the vial and concentration per mL are different figures. Everything is computed from concentration — verify mg/mL on YOUR vial, then use the calculator. Never carry syringe units from one vial to another without rechecking.
Do I need to stop before surgery?
Anesthesia societies advise holding GLP-1-class drugs before procedures because slowed gastric emptying raises aspiration risk. Tell every proceduralist you are on it and follow their hold window.
Regulatory status
FDA-approved as Ozempic (type 2 diabetes, 2017), Rybelsus (oral, 2019) and Wegovy (chronic weight management, 2021). A cardiovascular risk-reduction indication was added to Wegovy after SELECT.
During the 2022–2024 shortage, compounded semaglutide was lawful under shortage provisions. The FDA declared the shortage resolved in early 2025, ending most legal compounding — material sold as "research use" vials since then has no regulatory oversight at all.
Not a controlled substance. Prescription required for legitimate product.
Not prohibited by WADA.
How it compares
| Compared with | Difference that matters |
|---|---|
| Tirzepatide | Tirzepatide beat semaglutide head-to-head on both weight and HbA1c (SURPASS-2 and the SURMOUNT programme, ~20%+ versus ~15% average loss). Semaglutide answers back with the SELECT cardiovascular outcomes data and one fewer known drug interaction — it does not carry tirzepatide's oral-contraceptive warning. |
| Retatrutide | Retatrutide's Phase 2 numbers (~24%) top the class, but it remains investigational with no approval and no outcomes data. Semaglutide is the one with a decade of regulatory history behind it. |
| Oral semaglutide (Rybelsus) | Same molecule, ~1% bioavailability, strict empty-stomach dosing rules, and weaker average weight effects at approved doses. The injection is the format that produced the headline results. |
Frequently asked questions
How much weight will I lose?
The honest answer is a distribution, not a number: STEP 1 averaged 15% at the top dose over 68 weeks, with a third of participants losing 20%+ and roughly one in seven losing under 5%. Where you land in that spread is not predictable in advance.
Do I regain it all if I stop?
Most of it, on average, within a year — that is what the withdrawal data shows. Treat semaglutide like blood pressure medication: it works while you take it. The exception is people who use the drug window to rebuild training and eating habits and then taper deliberately.
Does it affect birth control?
Semaglutide's label carries no oral-contraceptive interaction — that warning belongs to tirzepatide. The class-wide caveat: severe vomiting can compromise any oral medication, pills included.
Semaglutide and levothyroxine?
Slowed gastric emptying can alter levothyroxine absorption. Keep the usual separation (levothyroxine alone, on waking) and recheck TSH about 6–8 weeks after starting or changing dose. DoseIQ flags this pairing automatically.
Can I drink on it?
Alcohol hits harder on a slowed stomach and an empty one — most people find their tolerance drops sharply. There is no formal interaction, but the practical advice is to halve expectations and hydrate.
Is compounded or grey-market semaglutide the same drug?
Chemically it may be; practically you cannot verify identity, concentration or sterility without testing. Since compounding wound down in 2025, quality variance in vial-format product is the biggest real-world risk with this compound — bigger than any label warning.
References
- STEP 1 — Once-Weekly Semaglutide in Adults with Overweight or ObesityWilding et al., New England Journal of Medicine, 2021
- SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesLincoff et al., New England Journal of Medicine, 2023
- Wegovy (semaglutide) Prescribing InformationU.S. Food and Drug Administration label
- FDA statement on compounded GLP-1 drugs as shortages resolveU.S. Food and Drug Administration, 2025
This page is an educational research reference and is not medical advice. Dose figures reflect the published record and what the community has converged on — starting points to weigh, not instructions. Consult a qualified healthcare provider before starting any protocol.